A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
← catalyst calendarNCT05231785 · readout in 974 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
60estimated
Sites
8
Countries
Canada, Netherlands, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-04 | actual | When the study began enrolling |
| Primary completion | 2029-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-20 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early-Onset Alzheimer Disease
Interventions
- Drug: ALN-APP — also filed as mivelsiran
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Frequency of Adverse Events
measured Up to 12 months
Part B: Frequency of Adverse Events
measured Up to 42 months
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed